<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of these analyses was to examine the efficacy of the intensive <z:chebi fb="0" ids="31654">gliclazide</z:chebi> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>-based <z:chebi fb="105" ids="17234">glucose</z:chebi> lowering regimen used in the ADVANCE trial in lowering the level of glycated <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> (HbA1c) </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 11,140 randomised patients were included in analyses of treatment efficacy </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment efficacy was also examined in subgroups defined by baseline characteristics and treatments </plain></SENT>
<SENT sid="3" pm="."><plain>At the end of 5 years follow-up, the mean HbA1c was reduced from 7.5% at baseline to 6.5% in those on intensive <z:chebi fb="105" ids="17234">glucose</z:chebi> control and to 7.3% in those on standard <z:chebi fb="105" ids="17234">glucose</z:chebi> control </plain></SENT>
<SENT sid="4" pm="."><plain>With intensive <z:chebi fb="105" ids="17234">glucose</z:chebi> lowering greater proportions achieved HbA1c levels of &lt; or =7.0%, &lt; or =6.5% and &lt; or =6.0% </plain></SENT>
<SENT sid="5" pm="."><plain>With intensive <z:chebi fb="105" ids="17234">glucose</z:chebi> lowering substantial reductions in HbA1c were observed across subgroups defined by baseline age, sex, duration of <z:mp ids='MP_0002055'>diabetes</z:mp>, BMI, HbA1c or treatment regimen (p&lt;0.0001) </plain></SENT>
<SENT sid="6" pm="."><plain>The main independent predictors of reduction in HbA1c during follow-up were baseline HbA1c, duration of <z:mp ids='MP_0002055'>diabetes</z:mp> and BMI </plain></SENT>
<SENT sid="7" pm="."><plain>There was no <z:mp ids='MP_0005456'>weight gain</z:mp> in the intensive <z:chebi fb="105" ids="17234">glucose</z:chebi> control group and severe <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> was uncommon, though more frequent than in the standard control group </plain></SENT>
<SENT sid="8" pm="."><plain>Intensive <z:chebi fb="105" ids="17234">glucose</z:chebi> control with a <z:chebi fb="0" ids="31654">gliclazide</z:chebi> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>-based regimen was well tolerated and consistently effective in lowering HbA1c across a broad range of patient with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>